INC Research Holdings (NASDAQ:INCR): 6 analysts have set the short term price target of INC Research Holdings (NASDAQ:INCR) at $50.83. The standard deviation of short term price target has been estimated at $3.49, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 56 and $47 respectively.
Many analysts have stated their opinion on the company shares. Avondale Partners maintains their rating on the shares of INC Research Holdings (NASDAQ:INCR). The current rating of the shares is Market Perform. Equity Analysts at the Firm raises the price target to $47 per share from $39 per share. The rating by the firm was issued on April 18, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Gibertini Michael, officer (President Clinical Development) of Inc Research Holdings, Inc., had unloaded 213,966 shares at an average price of $43.45 in a transaction dated on June 6, 2016. The total value of the transaction was worth $9,296,823.
INC Research Holdings (NASDAQ:INCR) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.93 points or 2.26% at $40.3 with 1,236,392 shares getting traded. Post opening the session at $41.13, the shares hit an intraday low of $39.9 and an intraday high of $41.4 and the price was in this range throughout the day. The company has a market cap of $2,185 million and the number of outstanding shares have been calculated to be 54,221,660 shares. The 52-week high of INC Research Holdings (NASDAQ:INCR) is $57.11 and the 52-week low is $34.19.
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Companys segment Clinical Development Services offers a variety of clinical development services, including global studies, clinical monitoring, investigator recruitment, patient recruitment, data management and study reports. The Companys segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Companys segment Global Consulting provides consulting services regarding clinical trial regulatory affairs, regulatory consulting services, quality assurance audits and pharmacovigilance consulting, non-clinical consulting and medical writing consulting.